MedPage Today on MSN
Parkinson's disease gets new treatment approved
FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...
The FDA approved AbbVie’s once-daily oral drug Juvmo (tavapadon) for adults with Parkinson’s disease. Phase 3 trials found ...
Head coach Sean McVay told reporters Monday that tight end Terrance Ferguson likely won't play against the Philadelphia ...
Los Angeles Rams tight end Colby Parkinson (shoulder) suffered an AC joint sprain in the Week 3 game against the Denver ...
Some people live with essential tremor for years and organically find ways to adapt. Others may begin avoiding activities.
This post is the first in a five-part series summarizing APDA’s recent “Ask the Expert” event on Smart Patients. During the ...
In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with ...
Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.
Dennis Haskins lived with Parkinson's disease for about eight years before his death at 75, keeping the diagnosis largely out ...
A new drug for Parkinson’s disease that seem to cause fewer serious side effects than some existing treatments has been ...
The FDA has approved tavapadon (AbbVie), a once-daily oral selective dopamine D1/D5 receptor partial agonist, for adults with ...
US Magazine on MSN
Saved By the Bell's Dennis Haskins Battled Parkinson's Before His Death
New details surrounding Dennis Haskins’ health have been revealed after his death at the age of 75. Haskins’ friend and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results